Elliott C. Dasenbrook

2.4k total citations
39 papers, 1.6k citations indexed

About

Elliott C. Dasenbrook is a scholar working on Pulmonary and Respiratory Medicine, Infectious Diseases and Epidemiology. According to data from OpenAlex, Elliott C. Dasenbrook has authored 39 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Pulmonary and Respiratory Medicine, 8 papers in Infectious Diseases and 7 papers in Epidemiology. Recurrent topics in Elliott C. Dasenbrook's work include Cystic Fibrosis Research Advances (30 papers), Tracheal and airway disorders (7 papers) and Antimicrobial Resistance in Staphylococcus (6 papers). Elliott C. Dasenbrook is often cited by papers focused on Cystic Fibrosis Research Advances (30 papers), Tracheal and airway disorders (7 papers) and Antimicrobial Resistance in Staphylococcus (6 papers). Elliott C. Dasenbrook collaborates with scholars based in United States, Canada and Australia. Elliott C. Dasenbrook's co-authors include Michael Boyle, Christian A. Merlo, Eddy Fan, Noah Lechtzin, Marie Diener‐West, Michael Drummond, David J. Murphy, Marshall Pitz, James F. Chmiel and Sarath Ranganathan and has published in prestigious journals such as JAMA, PLoS ONE and American Journal of Respiratory and Critical Care Medicine.

In The Last Decade

Elliott C. Dasenbrook

38 papers receiving 1.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Elliott C. Dasenbrook United States	20	1.3k	412	361	344	228	39	1.6k
Peter Hiatt United States	20	2.1k 1.7×	226 0.5×	778 2.2×	542 1.6×	153 0.7×	35	2.7k
Kelly Otto United States	9	1.7k 1.3×	107 0.3×	391 1.1×	263 0.8×	219 1.0×	13	1.9k
Rosemary Carzino Australia	19	1.9k 1.5×	152 0.4×	459 1.3×	476 1.4×	168 0.7×	40	2.3k
T. Pressler Denmark	19	784 0.6×	202 0.5×	399 1.1×	210 0.6×	79 0.3×	56	1.3k
Marta García‐Clemente Spain	20	629 0.5×	415 1.0×	225 0.6×	144 0.4×	155 0.7×	100	1.3k
Alexa A. Pragman United States	17	597 0.5×	407 1.0×	224 0.6×	672 2.0×	158 0.7×	29	1.4k
Douglas B. Hornick United States	19	465 0.4×	124 0.3×	287 0.8×	265 0.8×	59 0.3×	36	1.1k
Petra Schelstraete Belgium	18	426 0.3×	139 0.3×	174 0.5×	178 0.5×	36 0.2×	53	809
J. M. Wolter Australia	14	462 0.4×	90 0.2×	374 1.0×	104 0.3×	105 0.5×	17	1.0k
Hans‐Georg Posselt Germany	14	463 0.4×	137 0.3×	141 0.4×	102 0.3×	80 0.4×	38	808

Countries citing papers authored by Elliott C. Dasenbrook

Since Specialization

Citations

This map shows the geographic impact of Elliott C. Dasenbrook's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Elliott C. Dasenbrook with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Elliott C. Dasenbrook more than expected).

Fields of papers citing papers by Elliott C. Dasenbrook

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Elliott C. Dasenbrook. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Elliott C. Dasenbrook. The network helps show where Elliott C. Dasenbrook may publish in the future.

Co-authorship network of co-authors of Elliott C. Dasenbrook

This figure shows the co-authorship network connecting the top 25 collaborators of Elliott C. Dasenbrook. A scholar is included among the top collaborators of Elliott C. Dasenbrook based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Elliott C. Dasenbrook. Elliott C. Dasenbrook is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Dasenbrook, Elliott C., et al.. (2025). Real-world disease burden, mortality, and healthcare resource utilization associated with bronchiectasis. Chronic Respiratory Disease. 22. 4083735217–4083735217. 1 indexed citations

Sanders, Don B., Nicole Mayer-Hamblett, Margaret Rosenfeld, et al.. (2024). Characteristics of individuals with cystic fibrosis in the United States ineligible for ivacaftor and elexacaftor/tezacaftor/ivacaftor. Journal of Cystic Fibrosis. 24(2). 255–262. 5 indexed citations

Roesch, Erica A., Tracey L. Bonfield, Hillard M. Lazarus, et al.. (2022). A phase I study assessing the safety and tolerability of allogeneic mesenchymal stem cell infusion in adults with cystic fibrosis. Journal of Cystic Fibrosis. 22(3). 407–413. 15 indexed citations

Sawicki, Gregory S., Aricca D. Van Citters, Kathryn A. Sabadosa, et al.. (2021). Financial impacts of the COVID-19 pandemic on cystic fibrosis care: lessons for the future. Journal of Cystic Fibrosis. 20. 16–20. 12 indexed citations

Dasenbrook, Elliott C., Aliza K. Fink, Michael S. Schechter, et al.. (2019). Rapid lung function decline in adults with early-stage cystic fibrosis lung disease. Journal of Cystic Fibrosis. 19(4). 527–533. 2 indexed citations

Lehr, Carli J., M.A. Skeans, Elliott C. Dasenbrook, et al.. (2019). Effect of Including Important Clinical Variables on Accuracy of the Lung Allocation Score for Cystic Fibrosis and Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine. 200(8). 1013–1021. 22 indexed citations

West, Natalie E., Valeria Beckett, Raksha Jain, et al.. (2017). Standardized Treatment of Pulmonary Exacerbations (STOP) study: Physician treatment practices and outcomes for individuals with cystic fibrosis with pulmonary Exacerbations. Journal of Cystic Fibrosis. 16(5). 600–606. 63 indexed citations

Sawicki, Gregory S., Elliott C. Dasenbrook, Aliza K. Fink, & Michael S. Schechter. (2015). Rate of Uptake of Ivacaftor Use after U.S. Food and Drug Administration Approval among Patients Enrolled in the U.S. Cystic Fibrosis Foundation Patient Registry. Annals of the American Thoracic Society. 12(8). 1146–1152. 17 indexed citations

Jennings, Mark T., et al.. (2014). Eradication strategy for persistent methicillin-resistant Staphylococcus aureus infection in individuals with cystic fibrosis—the PMEP trial: study protocol for a randomized controlled trial. Trials. 15(1). 223–223. 21 indexed citations

10.

Chmiel, James F., Timothy R. Aksamit, Sanjay H. Chotirmall, et al.. (2014). Antibiotic Management of Lung Infections in Cystic Fibrosis. II. Nontuberculous Mycobacteria, Anaerobic Bacteria, and Fungi. Annals of the American Thoracic Society. 11(8). 1298–1306. 55 indexed citations

11.

Chmiel, James F., Timothy R. Aksamit, Sanjay H. Chotirmall, et al.. (2014). Antibiotic Management of Lung Infections in Cystic Fibrosis. I. The Microbiome, Methicillin-Resistant Staphylococcus aureus , Gram-Negative Bacteria, and Multiple Infections. Annals of the American Thoracic Society. 11(7). 1120–1129. 144 indexed citations

12.

Dasenbrook, Elliott C., Michael W. Konstan, & Donald R. VanDevanter. (2014). Association between the introduction of a new cystic fibrosis inhaled antibiotic class and change in prevalence of patients receiving multiple inhaled antibiotic classes. Journal of Cystic Fibrosis. 14(3). 370–375. 20 indexed citations

13.

Dasenbrook, Elliott C., Lan Lŭ, Shannon Donnola, et al.. (2013). Normalized T1 Magnetic Resonance Imaging for Assessment of Regional Lung Function in Adult Cystic Fibrosis Patients - A Cross-Sectional Study. PLoS ONE. 8(9). e73286–e73286. 20 indexed citations

14.

Dasenbrook, Elliott C., et al.. (2012). Isoflurane and ketamine anesthesia have different effects on ventilatory pattern variability in rats. Respiratory Physiology & Neurobiology. 185(3). 659–664. 8 indexed citations

15.

Endimiani, Andrea, Elliott C. Dasenbrook, Michael D. Reed, et al.. (2011). Emergence of Linezolid-Resistant Staphylococcus aureus after Prolonged Treatment of Cystic Fibrosis Patients in Cleveland, Ohio. Antimicrobial Agents and Chemotherapy. 55(4). 1684–1692. 76 indexed citations

16.

Dasenbrook, Elliott C., Dale M. Needham, Roy G. Brower, & Eddy Fan. (2011). Higher PEEP in Patients With Acute Lung Injury: A Systematic Review and Meta-Analysis. Respiratory Care. 56(5). 568–575. 31 indexed citations

17.

West, Natalie E., Noah Lechtzin, Michael Boyle, et al.. (2011). Chronic Macrolide Therapy Reduces Hospitalizations In Individuals With Cystic Fibrosis Colonized With Pseudomonas Aeruginosa. A1130–A1130.

18.

Dasenbrook, Elliott C., Christian A. Merlo, Noah Lechtzin, & Michael Boyle. (2009). The Impact of MRSA on Lung Function in Patients with Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine. 179(8). 735–735. 2 indexed citations

19.

Dasenbrook, Elliott C., Christian A. Merlo, Marie Diener‐West, Noah Lechtzin, & Michael Boyle. (2008). Persistent Methicillin-resistant Staphylococcus aureus and Rate of FEV1 Decline in Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine. 178(8). 814–821. 253 indexed citations

20.

Drummond, Michael, Elliott C. Dasenbrook, Marshall Pitz, David J. Murphy, & Eddy Fan. (2008). Inhaled Corticosteroids in Patients With Stable Chronic Obstructive Pulmonary Disease. JAMA. 300(20). 2407–2407. 264 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact